CARCINOMA, NON-SMALL-CELL LUNG

This study tested a new drug called sasanlimab (which helps the immune system fight cancer) combined with other targeted therapies in people with advanced non-small cell lung cancer. The trial was stopped early, but researchers were checking for safety and whether tumors shrank. …

This study tested a new drug called felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors (like ovarian, breast, lung, and others). The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

This study tested a drug called MORAb-202 in people with a type of advanced lung cancer (non-small cell lung cancer adenocarcinoma) that had spread and stopped responding to other treatments. The drug works like a guided missile, targeting a protein (folate receptor alpha) found …

This study tested a new targeted pill, pralsetinib, against standard chemotherapy for people with a specific type of advanced lung cancer (RET fusion-positive) who had not yet received treatment. The goal was to see if the targeted drug could delay cancer growth better than chemo…

This study looked at different immunotherapy drug combinations for people with advanced non-small cell lung cancer that had spread. It included two groups: those who had not yet received treatment and those whose cancer had worsened after standard therapies. The goal was to see i…

This early-phase study tested a new drug called QEQ278 in 30 adults with advanced lung, kidney, esophageal, or head and neck cancers that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminated early, so…

This early-stage study tested a new drug, PF-08046037, alone or with another drug (sasanlimab) in people with advanced lung, head and neck, skin, or pancreatic cancers. The goal was to check safety and how the body processes the drug. Only 8 people took part before the study was …

This early-phase study tested a new drug called PF-07284890, alone or with another drug (binimetinib), in people with advanced solid tumors that have a specific BRAF V600 mutation, including those with brain tumors. The main goals were to check safety, how the drug moves through …

This study tested a new drug called TRX-221 in people with a specific type of advanced lung cancer (EGFR mutant NSCLC) that had stopped responding to standard treatments. The goal was to see if TRX-221 was safe and could shrink tumors. The trial was stopped early after enrolling …

This study tested a new drug, PF-08046052/SGN-EGFRd2, in people with advanced solid tumors like colorectal, lung, head and neck, and pancreatic cancers that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The study was terminated e…

This study tested a new drug called BAT3306 against the standard treatment Keytruda, both given with chemotherapy, for people with stage IV non-squamous non-small cell lung cancer. The goal was to see if BAT3306 works as well and is as safe as Keytruda. The trial was stopped earl…

This study tested a new drug called bemcentinib combined with standard chemotherapy and immunotherapy for people with advanced non-squamous non-small cell lung cancer. The goal was to find a safe dose and see if the combination could shrink tumors, especially in patients with a s…

This study tested whether a special MRI scan (using xenon gas) can create a map of working lung tissue to help radiation beams avoid healthy areas. The goal was to reduce lung damage and improve quality of life after treatment. The study included 9 adults with non-small cell lung…

This early-phase study used special PET scans to track an experimental drug (BI 754111) in patients with advanced lung or head/neck cancer. The goal was to see where the drug goes in the body and how much reaches tumors. Only 8 patients were enrolled before the study was stopped …

This study aimed to see if using genome sequencing could help doctors choose better treatments for people with multiple lung adenocarcinoma tumors. Researchers planned to enroll 100 adults with early-stage, non-spread lung cancer. The study was terminated early, so results are li…